Currently on the market, there are five HDAC-related compounds approved for cancer treatment: vorinostat (suberoylanilide hydroxamic acid, SAHA), romidepsin, chidamide and Belinostat for T-cell lymphoma and panobinostat for the treatment of myeloma16,17. Here, HDAC9 is linked to cancer.